• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[The clinical value of soluble urokinase plasminogen activation receptor in febrile neutropenic patients with hematological malignancies after chemotherapy].

作者信息

Pu Y D, Deng Q, Cui R, Yuan T, Zhang R, Qi Y, Ma L, Li Y M

机构信息

Department of Hematology, Tianjin First Center Hospital, Tianjin 300192, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2017 Dec 14;38(12):1066-1068. doi: 10.3760/cma.j.issn.0253-2727.2017.12.013.

DOI:10.3760/cma.j.issn.0253-2727.2017.12.013
PMID:29365403
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7342195/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7b9/7342195/cbf570acdadf/cjh-38-12-1066-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7b9/7342195/cbf570acdadf/cjh-38-12-1066-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7b9/7342195/cbf570acdadf/cjh-38-12-1066-g001.jpg

相似文献

1
[The clinical value of soluble urokinase plasminogen activation receptor in febrile neutropenic patients with hematological malignancies after chemotherapy].可溶性尿激酶型纤溶酶原激活受体在血液系统恶性肿瘤化疗后发热性中性粒细胞减少患者中的临床价值
Zhonghua Xue Ye Xue Za Zhi. 2017 Dec 14;38(12):1066-1068. doi: 10.3760/cma.j.issn.0253-2727.2017.12.013.
2
The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.血清尿激酶型纤溶酶原激活物受体（suPAR）在血液恶性肿瘤发热性中性粒细胞减少症患者的诊断和随访中的意义。
Int J Infect Dis. 2013 Nov;17(11):e1056-9. doi: 10.1016/j.ijid.2013.04.004. Epub 2013 Jun 3.
3
Soluble form of urokinase-type plasminogen activator receptor as a diagnostic and prognostic marker in hematological patients with neutropenic fever.尿激酶型纤溶酶原激活物受体的可溶性形式作为中性粒细胞减少性发热血液病患者的诊断和预后标志物。
Leuk Lymphoma. 2014 Mar;55(3):718-21. doi: 10.3109/10428194.2013.811582. Epub 2013 Jul 22.
4
Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study.将国家早期预警评分与可溶性尿激酶型纤溶酶原激活物受体 (suPAR) 相结合可改善急性内科患者的风险预测：一项基于登记的队列研究。
Crit Care Med. 2018 Dec;46(12):1961-1968. doi: 10.1097/CCM.0000000000003441.
5
Elevated preoperative suPAR is a strong and independent risk marker for postoperative complications in patients undergoing major noncardiac surgery (SPARSE).术前 suPAR 升高是行大非心脏手术患者术后并发症的一个强而独立的风险标志物（SPARSE）。
Surgery. 2022 Jun;171(6):1619-1625. doi: 10.1016/j.surg.2021.10.012. Epub 2021 Nov 1.
6
The expenditures related to the use of antifungal drugs in patients with hematological cancers: a cost analysis.血液系统癌症患者使用抗真菌药物的相关支出：成本分析。
Clinicoecon Outcomes Res. 2015 Nov 3;7:537-43. doi: 10.2147/CEOR.S92455. eCollection 2015.
7
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.通过测定卵巢癌FIGO II和III期患者血清中的尿激酶型纤溶酶原激活剂（uPA）和可溶性尿激酶型纤溶酶原激活剂受体（suPAR）来监测铂/紫杉醇化疗方案的化疗成功率。
Bosn J Basic Med Sci. 2007 May;7(2):111-6. doi: 10.17305/bjbms.2007.3063.
8
Augmented Renal Clearance and Hypoalbuminemia-Induced Low Vancomycin Trough Concentrations in Febrile Neutropenic Patients With Hematological Malignancies.血液系统恶性肿瘤发热性中性粒细胞减少患者的肾清除率增加及低白蛋白血症导致万古霉素谷浓度降低
Cureus. 2022 Sep 25;14(9):e29568. doi: 10.7759/cureus.29568. eCollection 2022 Sep.
9
The diagnostic value of soluble urokinase plasminogen activator receptor compared with C-reactive protein and procalcitonin in children with febrile neutropenia.可溶性尿激酶型纤溶酶原激活物受体与C反应蛋白及降钙素原相比在儿童发热性中性粒细胞减少症中的诊断价值
Pediatr Hematol Oncol. 2016 Apr;33(3):200-8. doi: 10.3109/08880018.2016.1155100. Epub 2016 Apr 8.
10
Cell Cycle Biomarkers and Soluble Urokinase-Type Plasminogen Activator Receptor for the Prediction of Sepsis-Induced Acute Kidney Injury Requiring Renal Replacement Therapy: A Prospective, Exploratory Study.细胞周期生物标志物和可溶性尿激酶型纤溶酶原激活物受体预测需要肾脏替代治疗的脓毒症相关性急性肾损伤：一项前瞻性探索性研究。
Crit Care Med. 2019 Dec;47(12):e999-e1007. doi: 10.1097/CCM.0000000000004042.

本文引用的文献

1
The diagnostic value of soluble urokinase plasminogen activator receptor (suPAR) compared to C-reactive protein (CRP) and procalcitonin (PCT) in children with systemic inflammatory response syndrome (SIRS).可溶性尿激酶型纤溶酶原激活物受体（suPAR）与C反应蛋白（CRP）和降钙素原（PCT）相比在儿童全身炎症反应综合征（SIRS）中的诊断价值。
J Infect Chemother. 2017 Jan;23(1):17-22. doi: 10.1016/j.jiac.2016.08.015. Epub 2016 Oct 19.
2
Role of biomarkers in the management of antibiotic therapy: an expert panel review: I - currently available biomarkers for clinical use in acute infections.生物标志物在抗生素治疗管理中的作用：专家小组综述：I - 目前用于急性感染临床应用的生物标志物。
Ann Intensive Care. 2013 Jul 9;3(1):22. doi: 10.1186/2110-5820-3-22.
3
The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.血清尿激酶型纤溶酶原激活物受体（suPAR）在血液恶性肿瘤发热性中性粒细胞减少症患者的诊断和随访中的意义。
Int J Infect Dis. 2013 Nov;17(11):e1056-9. doi: 10.1016/j.ijid.2013.04.004. Epub 2013 Jun 3.
4
Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review.suPAR 作为全身炎症或感染患者的生物标志物的效用：系统评价。
Intensive Care Med. 2012 Sep;38(9):1418-28. doi: 10.1007/s00134-012-2613-1. Epub 2012 Jun 16.
5
Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia.可溶性尿激酶型纤溶酶原激活物受体（suPAR）水平升高可预测金黄色葡萄球菌菌血症的死亡率。
Eur J Clin Microbiol Infect Dis. 2011 Nov;30(11):1417-24. doi: 10.1007/s10096-011-1236-8. Epub 2011 Apr 12.
6
Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study.血浆可溶性尿激酶型纤溶酶原激活物受体水平可预测菌血症患者的疾病严重程度和病死率：一项前瞻性队列研究。
J Intern Med. 2011 Jul;270(1):32-40. doi: 10.1111/j.1365-2796.2011.02363.x. Epub 2011 Mar 21.
7
Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.循环可溶性尿激酶型纤溶酶原激活物受体在重症监护病房治疗的第一周内稳定升高，并可预测危重症患者的死亡率。
Crit Care. 2011;15(1):R63. doi: 10.1186/cc10037. Epub 2011 Feb 16.
8
Soluble urokinase plasminogen activator receptor during allogeneic stem cell transplantation.可溶性尿激酶型纤溶酶原激活物受体在异基因干细胞移植中的作用。
Scand J Immunol. 2011 Apr;73(4):325-9. doi: 10.1111/j.1365-3083.2011.02511.x.
9
suPAR: the molecular crystal ball.可溶性尿激酶型纤溶酶原激活物受体：分子水晶球
Dis Markers. 2009;27(3):157-72. doi: 10.3233/DMA-2009-0657.
10
High mortality risk among individuals assumed to be TB-negative can be predicted using a simple test.通过一项简单测试可以预测假定为结核阴性个体中的高死亡风险。
Trop Med Int Health. 2009 Sep;14(9):986-94. doi: 10.1111/j.1365-3156.2009.02328.x.